ClinicalTrials.gg
CompletedNCT06383312Updated Nov 5, 2026

Magnetic Reflexologic Insoles for Primary Dysmenorrhea

An interventional study of Reflexologic Magnetic Insole Group and Orthopedic Insole Group in Primary Dysmenorrhea, sponsored by Istanbul Medipol University Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Istanbul Medipol University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jun 2022, registered Apr 2024).
Updated Nov 5, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Dysmenorrhea with a site in Turkey — 19 open to participants now, 23 under way, none of them phase 3. Dysmenorrhea · Turkey.

Enrollment
36th of 72
60 · median 60
Started
2022
with 6 others
No phase
70 of 81
16 open now
Registered
39th of 81
by date
Lead sponsor
3 of 81
Istanbul Medipol University Hospital

Among the 81 studies in Dysmenorrhea with a site in Turkey, this one is the 36th largest by enrollment of the 72 interventional ones that give a count, is one of 7 that started in 2022, is one of 70 with no phase, and was the 39th registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

19 of the 81 studies in Dysmenorrhea with a site in Turkey are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 30 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Dysmenorrhea with a site in Turkey, or all of them as a file.
02

Study summary

In the study, easy-to-access and easy-to-use reflexologic magnetic insoles were used in women with primary dysmenorrhea who did not want to receive medical treatment.

Read the detailed description

Sixty women diagnosed with primary dysmenorrhea following examination by a gynecologist were included in the study. The participants were randomly assigned to two groups. Participants in the Reflexologic Magnetic Insoles Sham Group used insoles.

03

Conditions studied

  • Primary Dysmenorrhea

Keywords

  • Dysmenorrhea
  • Reflexology
  • Pain
  • Foot Orthoses
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having been diagnosed with primary dysmenorrhea
  • Visual Analogue Scale (VAS) value is 3 and above
  • The patient has cooperation
  • Having regular menstruation

Exclusion criteria

Exclusion Criteria:

  • Getting pregnant during treatment
  • Using analgesic medication
  • Visual Analogue Scale (VAS) value should be between 0-3
  • Having pain in another part of the body
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Reflexologic Magnetic Insoles Group

    Participants placed the insoles inside their shoes and used them for at least 7 hours a day, every day, for 12 weeks.

    Device: Reflexologic Magnetic Insole Group

  • Sham comparator
    Orthopedic Insoles Group

    Participants placed the insoles inside their shoes and used them for at least 7 hours a day, every day, for 12 weeks.

    Device: Orthopedic Insole Group

Interventions

  • DeviceReflexologic Magnetic Insole Group

    Reflexologic magnetic insoles were used for at least 7 hours a day, every day, for 12 weeks by participants diagnosed with primary dysmenorrhea. The effectiveness of the insoles was then compared.

  • DeviceOrthopedic Insole Group

    Orthopedic insoles (sham) were used for at least 7 hours a day, every day, for 12 weeks by participants diagnosed with primary dysmenorrhea. The effectiveness of the insoles was then compared.

06

What researchers measure

Primary outcomes

  1. McGill Pain Questionnaire-Short Form Total Score

    It evaluates the sensory dimension of pain and the affective dimension of pain. Affective and sensory dimension scores of pain are measured with a Likert-type scale (0-No pain, 3-Severe Pain). The total pain dimension subparametric is the sum of the sensory dimension and the affective dimension of the pain. Total pain intensity is measured with a 6-point Likert-type scale (0-No pain, 5-Unbearable Pain). A high score indicates a high level of pain.

    Time frame: 12 weeks

Secondary outcomes

  1. Menstruation Attitude Questionnaire

    Valuated subdimensions include menstruation as a deliberating event, menstruating as a bothersome event, menstruation as a natural event, anticipation and prediction of the onset of menstruation, and denial of any effects of menstruation. The scale is evaluated with a 5-point Likert-type." A high mean score indicates a "positive" attitude toward menstruation.

    Time frame: 12 weeks

  2. Visual Analogue Scale (VAS)

    The Visual Analogue Scale (VAS) is used to convert non-numerical values to digital. The value 0 means I have no pain, 10 means I have unbearable pain. The person marks his pain on this ruler. It measures the intensity of the pain.

    Time frame: 12 weeks

  3. Menstruation Symptom Questionnaire

    It contains 24 items. It is a 5-point Likert type scale. Participants are asked to evaluate the symptoms that occur during menstruation as a-never (1), b-rarely (2), c-sometimes (3), d-often (4) and e-always (5). The overall score of the scale is calculated by taking the average of the total score obtained from the scale items. A higher score indicates that the symptoms are experienced more clearly.

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Aug 2024, 25 months.

Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 25 months is above that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start May 2024 → Jun 2022 and completion Sep 2024 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2024
First posted
Apr 25, 2024
StartActual
Jun 20, 2022was May 2024
Primary completionActual
Aug 19, 2024
CompletionActual
Sep 14, 2026was Sep 2024
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 5, 2026
Start date
May 2024→Jun 20, 2022 (actual)
Nov 5, 2026
Study completion
Sep 2024→Sep 14, 2026 (actual)
Nov 5, 2026
Primary outcomes
1 edited, 3 removed
What changed in the outcomes
  • EditedMcGill Pain Questionnaire-Short Form: Total ScoreTime frame: 12 weeks
  • RemovedMenstruation Attitude QuestionnaireTime frame: 12 weeks
  • RemovedMenstruation Symptom QuestionnaireTime frame: 12 weeks
  • RemovedVisual Analogue Scale (VAS)Time frame: 12 weeks
Nov 5, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • AddedMenstruation Attitude QuestionnaireTime frame: 12 weeks
  • AddedVisual Analogue Scale (VAS)Time frame: 12 weeks
  • AddedMenstruation Symptom QuestionnaireTime frame: 12 weeks
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Completed
    Start date May 2024→Jun 20, 2022 (now actual)
    Study completion Sep 2024→Sep 14, 2026 (now actual)
    Primary outcomes 1 edited, 3 removed
    What changed in the outcomes
    • EditedMcGill Pain Questionnaire-Short Form: Total ScoreTime frame: 12 weeks
    • RemovedMenstruation Attitude QuestionnaireTime frame: 12 weeks
    • RemovedMenstruation Symptom QuestionnaireTime frame: 12 weeks
    • RemovedVisual Analogue Scale (VAS)Time frame: 12 weeks
    Secondary outcomes 3 added
    What changed in the outcomes
    • AddedMenstruation Attitude QuestionnaireTime frame: 12 weeks
    • AddedVisual Analogue Scale (VAS)Time frame: 12 weeks
    • AddedMenstruation Symptom QuestionnaireTime frame: 12 weeks
    + 6 other changes: verification date, description, arm descriptions, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06383312
Responsible party
gizem boztas (Assistant Professor, Istanbul Medipol University Hospital) — Principal investigator
First posted
Apr 25, 2024
Start date
Jun 20, 2022
Primary completion
Aug 19, 2024
Completion
Sep 14, 2026
Last update
Nov 5, 2026

Study contacts

Gizem BOZTAŞ ELVERİŞLİ, Ph.D
study director · Medipol University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion